DrugPatentWatch Database Preview
Hoffmann-la Roche Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for HOFFMANN-LA ROCHE, and what generic alternatives to HOFFMANN-LA ROCHE drugs are available?
HOFFMANN-LA ROCHE has two approved drugs.
There are three US patents protecting HOFFMANN-LA ROCHE drugs.
There are seventy-five patent family members on HOFFMANN-LA ROCHE drugs in thirty-eight countries and nineteen supplementary protection certificates in fourteen countries.
Summary for Hoffmann-la Roche
| International Patents: | 75 |
| US Patents: | 3 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Hoffmann-la Roche: | See patent lawsuits for Hoffmann-la Roche |
Drugs and US Patents for Hoffmann-la Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Hoffmann-la Roche | INVIRASE | saquinavir mesylate | TABLET;ORAL | 021785-001 | Dec 17, 2004 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | 9,440,922 | Start Trial | Y | Start Trial | |||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hoffmann-la Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hoffmann-la Roche | INVIRASE | saquinavir mesylate | TABLET;ORAL | 021785-001 | Dec 17, 2004 | 5,196,438*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hoffmann-la Roche Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Netherlands | 300876 | Start Trial |
| Lithuania | PA2017017 | Start Trial |
| Portugal | 2441753 | Start Trial |
| Canada | 2764653 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hoffmann-la Roche Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0432695 | 32/1996 | Austria | Start Trial | PRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| 2441753 | 2017/026 | Ireland | Start Trial | PRODUCT NAME: ALECTINIB OR SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/16/1169/001 20170216 |
| 2441753 | 122017000048 | Germany | Start Trial | PRODUCT NAME: ALECTINIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/16/1169 20170216 |
| 2441753 | 2017026 | Norway | Start Trial | PRODUCT NAME: ALEKTINIB ELLER SALT ELLER SOLVAT; REG. NO/DATE: EU/1/16/1169 20170307 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
